SAVIOR LIFETEC CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.75 TWD | -3.71% |
|
-2.12% | -7.57% |
| Sales 2022 | 1.27B 39.22M | Sales 2023 | 1.05B 32.54M | Capitalization | 7.13B 221M |
|---|---|---|---|---|---|
| Net income 2022 | 36M 1.12M | Net income 2023 | 30M 929K | EV / Sales 2022 | 5.78 x |
| Net cash position 2022 | 549M 17M | Net cash position 2023 | 1.07B 33.05M | EV / Sales 2023 | 5.77 x |
| P/E ratio 2022 |
225
x | P/E ratio 2023 |
240
x | Employees | 384 |
| Yield 2022 |
0.42% | Yield 2023 |
-
| Free-Float | 84.7% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.71% | ||
| 1 week | -2.12% | ||
| Current month | -3.04% | ||
| 1 month | +0.48% | ||
| 3 months | +4.80% | ||
| 6 months | +6.68% | ||
| Current year | -7.57% |
1 week
20.75
22.15
1 month
20.2022.50
Current year
18.1024.20
1 year
16.7527.00
3 years
15.4030.29
5 years
15.4042.73
10 years
14.3454.74
| Managers | Title | Age | Since |
|---|---|---|---|
Yung-Fa Chen
CEO | Chief Executive Officer | - | 18-12-02 |
Man Chin Ku
CHM | Chairman | - | 13-05-02 |
Emma Wang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Man Chin Ku
CHM | Chairman | - | 13-05-02 |
| Director/Board Member | - | 10-06-23 | |
Chia Yue Wu
BRD | Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.67% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 20.75 | -3.71% | 2,387,629 |
| 24-05-02 | 21.55 | +0.70% | 1,499,445 |
| 24-04-30 | 21.4 | 0.00% | 1,103,054 |
| 24-04-29 | 21.4 | +0.94% | 2,253,378 |
| 24-04-26 | 21.2 | -2.08% | 1,967,808 |
End-of-day quote Taipei Exchange, May 02, 2024
More quotes
SAVIOR LIFETEC CORPORATION is a Taiwan-based company principally engaged in the development, manufacture and distribution of antibiotic bulk pharmaceutical chemicals and intermediates. The Companyâs products portfolio mainly consists of Meropenem and Imipenem/Cilastatin, Meropenem as well as Ertapenem, among others, which are used as spectrum antibiotics. In addition, it is involved in the provision of APIs intermediates as well as bio-pharmaceutical technology services. The Company distributes its products to Europe, the Americas, Asia and other markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -7.57% | 204M | |
| +19.98% | 43.48B | |
| +20.67% | 22.65B | |
| +14.56% | 14.73B | |
| +14.32% | 13.79B | |
| +44.72% | 12.04B | |
| -8.37% | 7.08B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +11.90% | 5.47B |
- Stock Market
- Equities
- 4167 Stock
